Focus on Clinical 12/15/06

Fri, 12/15/2006 - 8:42am
Immtech Initiates Phase II Trial of Pafuramidine Maleate for Malaria
Immtech Pharmaceuticals Inc., New York, has initiated a phase II trial in the US of its oral drug candidate, pafuramidine maleate, as a prophylaxis to prevent malaria infections for travelers to endemic regions.
Full Article

Genzyme Begins Phase II Study of Clolar in Leukemia
Genzyme Corp., Cambridge, Mass., has begun treating patients in a phase II clinical trial examining the safety and effectiveness of Clolar (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia who are unlikely to benefit from standard therapy.
Full Article

Genta Initiates Pilot Trial for Patients with Melanoma
Genta Inc., Berkeley Heights, N.J., initiated a new clinical study that will evaluate its lead anticancer drug, Genasense (oblimersen sodium) in patients with advanced melanoma. The new study represents the rapid clinical translation of preclinical results that demonstrated marked anticancer synergy when Genasense was combined with Abraxane and Temodar.
Full Article

Sangamo Begins Phase II Trial of Therapy for Diabetic Neuropathy
Sangamo BioSciences Inc., Richmond, Calif., has initiated a double-blind, placebo-controlled, repeat-dosing multi-center phase II clinical trial of SB-509 for diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.
Full Article

AEterna Zentaris to Initiate Phase III Program with Cetrorelix
AEterna Zentaris Inc., Quebec, Canada, plans to initiate a phase III program in benign prostatic hyperplasia before year-end with its luteinizing hormone-releasing a hormone antagonist compound, cetrorelix, after its Investigational New Drug Application was accepted by the US Food and Drug Administration.
Full Article

Dynavax Initiates Phase I Trial in Metastatic Colorectal Cancer
Dynavax Technologies Corp., Berkeley, Calif., announced the initiation of a phase I dose-escalation clinical trial of its TLR9 agonist in combination with a standard chemotherapeutic regimen for metastatic colorectal cancer.
Full Article

Osteologix Initiates Phase II Trial of Osteoporosis Drug
Osteologix Inc., San Francisco, has initiated a randomized, double-blind, placebo-controlled phase II clinical trial of NB S101, its investigational drug for osteoporosis. Osteologix plans to enroll approximately 275 women and treat them for 12 weeks in the UK and Denmark.
Full Article

Northern Therapeutics Begins Gene Therapy Trial for PAH
United Therapeutics Corp. announced that its Canadian affiliate, Northern Therapeutics Inc., Montreal, has commenced the first-ever human trial of a novel, cell-mediated gene therapy to treat pulmonary arterial hypertension (PAH).
Full Article

China Biopharmaceuticals Initiates Clinical Trials for Ulcers
China Biopharmaceuticals Holdings Inc. (CHBP), Beijing, has initiated clinical trials to evaluate the safety and efficacy of Sofalcone to treat digestive ulcers. CHBP is one of only three companies approved by the Chinese State Food and Drug Administration to conduct clinical trials for this drug in China.
Full Articleope



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.